Johnson & Johnson reports IMAAVY long-term myasthenia gravis data

• Johnson & Johnson reported two-year results from the Phase 2/3 Vibrance-MG study of IMAAVY in adolescents with generalized myasthenia gravis.
• Adolescents maintained improvements in daily function and muscle strength through Week 108, with no new safety signals identified.
• A separate adult treatment-switch survey showed improvements among patients who moved to IMAAVY from prior advanced therapies.

Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.

In the ongoing Phase 2/3 Vibrance-MG study, adolescents with anti-acetylcholine receptor (anti-AChR)-positive generalized myasthenia gravis maintained improvements in daily functioning and muscle strength through Week 108.

Among adolescents with available data, mean changes from baseline were a reduction of 2.88 points on the daily-function scale and an 8.25-point improvement on the muscle-strength scale.

The company reported that among six adolescents who were receiving corticosteroids at study entry, three reduced their corticosteroid dose and one discontinued treatment after two years on IMAAVY.

No new safety signals were observed through up to two years of treatment.

In a separate retrospective clinician survey involving 97 adults with generalized myasthenia gravis who switched from prior advanced therapies to IMAAVY, 73.2% of patients were reported as being “much improved” or “very much improved.”

Among adult patients receiving prednisone, 76.4% reduced their dose and 5.5% discontinued prednisone treatment after switching to IMAAVY.